Menu
Home
Portfolio
What we do
đź”˝

EIR Program

Team
Contact
Portfolio

nCode

[SQAAS] Sequence as a service

Business Unit:
Lifesciences
Company:
nCode
Website:
View Live
nCode
nCode

Overview

‍

nCode Bio is an innovative AI/ML powered generative Sequence as a Service (SqAAS) suite that empower researchers discover, validate and derisk novel “multi-omic” sequences for enabling next generation therapeutics.
‍AI/ML-enabled drug discovery suite combined with leveraging the expertise in early R&D to late stage therapeutic development programs in cell and gene therapy (CGT), genomics, immuno-oncology, CRISPR, iPSCs, and biotherapeutics nCode delivers efficient, effective and safe sequences

Key features include:

Advanced generative AI and LLMs.
Novel target discovery and mapping targets to existing disease indications.
Robotic micro-experiments with integrated analyses enabling de-risking and accelerating the discovery and development funnel.
Short turnaround times.
Cross-disciplinary approach.
Immunogenicity prediction/ risk assessment.

‍

nCode

Focus Areas

Medical text img
Solid text img
tab second img
tab first img
Chronic Diseases

Problem:
80% of adults 65+ live with at least one incurable chronic disease.
Need:
‍Go beyond symptom management to restore cellular health.
Solution:
‍AI-guided reprogramming therapeutics that reverse or halt disease at its biological root.

Slow, Costly Discovery

Problem:
Drug development takes 10–15 years and over $2.6B with 90% failure rates.
Need:
‍Faster, smarter ways to design adaptive therapies.
Solution:
‍AI-native platform accelerating discovery and precision design of next-gen medicines.

Loss of Regeneration

Problem:
Aging and complex diseases damage cells the body can’t repair.
Need:
‍Safe, targeted rejuvenation of tissues and organs.
Solution:
‍Partial cellular reprogramming to restore and renew function without altering identity.

The Code Ecosystem

‍

At the heart of the mRNA Therapeutic ecosystem, nCode acts as a pivotal partner, driving the process from early research through to pre-clinical stages. We provide comprehensive support in target identification, validation, lead optimization, and preclinical testing. The nCode platform employs an "Intra-Extra Integration" approach, absorbing, generating, validating, computing, and analyzing data to continuously enrich our Synapse model.

This approach supports a wide range of applications, integrates digital and physical infrastructure, and is backed by robust informatics, dashboards, reports, and continuous learning, all designed to scale and enhance the efficiency and success of RNA therapeutic development.

‍

Explore nCode Biosciences

Other Portfolio Companies

Renue Bio
Renue Bio
Renue Bio
Formd
Formd
Formd